Rapid lung function improvement patients can feel as early as
Week 22,4,6,8

Lung function improvement through Week 52

Baseline blood EOS ≥300 cells/μL (QUEST, post hoc analysis)

  • 500 mL improvement from baseline in pre-bronchodilator FEV1 at Week 52 with DUPIXENT 300 mg Q2W + SOC (n=129) vs 250 mL with
    placebo + SOC (n=61) (LSM difference: 250 mL [95% CI: 110, 390 mL])4,6,8

Results are descriptive. Definitive conclusions cannot be made as this was a post-hoc analysis. There are limitations on sample
size and data were not multiplicity controlled.

Sustained lung function improvement patients can feel2,4,5,a,b

UP TO
~3YEARS OFBREATHING RELIEF

  • 450 mL improvement in FEV1 at Week 96 in the DUPIXENT/DUPIXENT group (n=92) from 1.84 L at baseline
    in the parent study for patients enrolled from QUEST (baseline blood EOS ≥300 cells/μL, TRAVERSE OLE
    study, post hoc analysis)4
    • 440 mL improvement in FEV1 at Week 96 in the placebo/DUPIXENT group (n=50)
      from 1.89 L at baseline in the parent study for patients enrolled from QUEST4

Results are descriptive. Definitive conclusions cannot be made as this was
a post hoc analysis of open-label extension data.

Data were not multiplicity controlled and there are limitations associated
with open-label study design, including lack of comparator arm, decreasing
sample size, and potential continued involvement of responders and
attrition of nonresponders.

a1.84 L was the baseline FEV1 level from QUEST (n=129) compared with a
placebo value of 1.89 L (n=61).4

bFEV1 was assessed in the exposed population (observed cases) using
descriptive statistics.5

EOS, eosinophils; FEV1, forced expiratory volume in 1 second; ICS, inhaled
corticosteroid; ITT, intention-to-treat; LSM, least squares mean; OLE,
open-label extension; Q2W, once every 2 weeks; SOC, standard of care.